HILLSIDE, NJ, March 12, 2007—InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. (NASDAQ: INBP), today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV™ vaccine technology. The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the Contract Research Organization led by Dr. Vidadi Yusibov, through which BioTech executes its vaccine-related development activities.
The results, reported in the respected peer-reviewed scientific journal Vaccine, demonstrated pre-clinical efficacy of key HPV proteins produced by the AIPwLV™ technology, which induced specific immune responses and protected against HPV challenge infection. HPV is the primary etiologic agent of cervical cancer, which represents the third leading cause of cancer-related death among women worldwide. The reported results support the possibility of producing prophylactic and therapeutic HPV vaccines using the AIPwLV™ technology.
The studies also demonstrated that other vaccine candidates made using the AIPwLV™ technology induced specific immune responses and conferred complete protection against lethal doses of anthrax and plague, two substances considered as likely bioterrorism agents.
"The AIPwLV™ technology achieves rapid, high level production of antigens, antibodies and therapeutic proteins in non-genetically modified plants utilizing a proprietary launch-vector technology," said Dr. Yusibov, the Executive Director of CMB. "It offers rapid, unparalleled scalability of vaccine production and cost efficiency, addressing the principal concerns affecting current methods of vaccine production, particularly where large scale or rapid inoculation is desired," added Dr. Yusibov.
About Integrated BioPharma, Inc. Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
Contact: Jeffery Leach, VP Dina Masi, CFO Integrated BioPharma Inc 888-319-6962 email@example.com